Spencer J Collis
Overview
Explore the profile of Spencer J Collis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1713
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cheng V, Vaughn-Beaucaire P, Shaw G, Kriegs M, Droop A, Psakis G, et al.
Cell Rep
. 2025 Mar;
44(3):115361.
PMID: 40053455
Cancer cells undergo morphological changes and phenotype switching to promote invasion into healthy tissues. Manipulating the transitional morphological states in cancer cells to prevent tumor dissemination may enhance survival and...
2.
Zhao A, Maple L, Jiang J, Myers K, Jones C, Gagg H, et al.
Cell Death Dis
. 2024 Dec;
15(12):881.
PMID: 39638786
SUMOylation, the covalent attachment of the small ubiquitin-like modifier (SUMO) to target proteins, and its reversal, deSUMOylation by SUMO proteases like Sentrin-specific proteases (SENPs), are crucial for initiating cellular responses...
3.
Jones C, Vanderlinden A, Rominiyi O, Collis S
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473223
Glioblastoma is an aggressive, incurable brain cancer with poor five-year survival rates of around 13% despite multimodal treatment with surgery, DNA-damaging chemoradiotherapy and the recent addition of Tumour Treating Fields...
4.
Derby S, Dutton L, Strathdee K, Stevenson K, Koessinger A, Jackson M, et al.
Neuro Oncol
. 2023 Nov;
26(4):625-639.
PMID: 37936324
Background: Glioblastomas have highly infiltrative growth patterns that contribute to recurrence and poor survival. Despite infiltration being a critical therapeutic target, no clinically useful therapies exist that counter glioblastoma invasion....
5.
Gagg H, Williams S, Conroy S, Myers K, McGarrity-Cottrell C, Jones C, et al.
F1000Res
. 2023 Oct;
12:954.
PMID: 37799492
With diminishing returns and high clinical failure rates from traditional preclinical and animal-based drug discovery strategies, more emphasis is being placed on alternative drug discovery platforms. approaches represent a departure...
6.
Vanderlinden A, Jones C, Myers K, Rominiyi O, Collis S
Br J Cancer
. 2023 Sep;
129(11):1829-1840.
PMID: 37777579
Background: High-grade gliomas are primary brain cancers with unacceptably low and persistent survival rates of 10-16 months for WHO grade 4 gliomas over the last 40 years, despite surgical resection...
7.
Patel P, Alghamdi A, Shaw G, Legge C, Glover M, Freeman D, et al.
Nanotheranostics
. 2023 Jan;
7(1):102-116.
PMID: 36593801
Delivering therapies to deeply seated brain tumours (BT) is a major clinical challenge. Magnetic drug targeting (MDT) could overcome this by rapidly transporting magnetised drugs directly into BT. We have...
8.
Williams S, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, et al.
Expert Rev Mol Med
. 2022 Oct;
24:e39.
PMID: 36184897
Despite advances in cancer genomics and the increased use of genomic medicine, metastatic cancer is still mostly an incurable and fatal disease. With diminishing returns from traditional drug discovery strategies,...
9.
Rominiyi O, Collis S
Mol Oncol
. 2021 May;
16(1):11-41.
PMID: 34036721
Glioblastoma is the most frequently diagnosed type of primary brain tumour in adults. These aggressive tumours are characterised by inherent treatment resistance and disease progression, contributing to ~ 190 000...
10.
Carmell N, Rominiyi O, Myers K, McGarrity-Cottrell C, Vanderlinden A, Lad N, et al.
Cancers (Basel)
. 2021 Mar;
13(5).
PMID: 33668183
Brain tumours kill more children and adults under 40 than any other cancer, with approximately half of primary brain tumours being diagnosed as high-grade malignancies known as glioblastomas. Despite de-bulking...